Diabetes - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols FTL and GLP1R	Name 1 ferritin light chain	Name2 glucagon like peptide 1 receptor	Pathway 1 Scavenging by Class A Receptors Golgi Associated Vesicle Biogenesis Neutrophil degranulation Iron uptake and transport	Pathway 2 Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Glucagon-like Peptide-1 (GLP1) regulates insulin secretion G alpha (s) signalling events Glucagon-type ligand receptors	Drugs 1 Iron Dextran Protoporphyrin Ferric pyrophosphate Sodium ferric gluconate complex Ferric pyrophosphate citrate	Drugs 2 Glucagon Exenatide Liraglutide Albiglutide Dulaglutide Lixisenatide Semaglutide Taspoglutide Tirzepatide Efpeglenatide Glutazumab	Diseases 1 Neurodegeneration with brain iron accumulation (NBIA); Hallervorden-Spatz syndrome; Neuroferritinopathy; Aceruloplasminemia	Diseases 2
Novel Novel	Symbols FGA and SYCE1L	Name 1 fibrinogen alpha chain	Name2 synaptonemal complex central element protein 1 like	Pathway 1 Platelet degranulation ER-Phagosome pathway Common Pathway of Fibrin Clot Formation MyD88:MAL(TIRAP) cascade initiated on plasma membrane Integrin cell surface interactions Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) MAP2K and MAPK activation Regulation of TLR by endogenous ligand Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Post-translational protein phosphorylation Signaling downstream of RAS mutants Signaling by RAF1 mutants Amyloid fiber formation	Pathway 2	Drugs 1 Alteplase Reteplase Anistreplase Tenecteplase Sucralfate Zinc Alfimeprase Ancrod EP-2104R Lanoteplase Thrombin Prothrombin Human thrombin Thrombin alfa Anti-inhibitor coagulant complex Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Familial amyloidosis Inherited thrombophilia Afibrinogenemia; Dysfibrinogenemia	Diseases 2
Novel Novel	Symbols FGA and SERPINF2	Name 1 fibrinogen alpha chain	Name2 serpin family F member 2	Pathway 1 Platelet degranulation ER-Phagosome pathway Common Pathway of Fibrin Clot Formation MyD88:MAL(TIRAP) cascade initiated on plasma membrane Integrin cell surface interactions Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) MAP2K and MAPK activation Regulation of TLR by endogenous ligand Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Post-translational protein phosphorylation Signaling downstream of RAS mutants Signaling by RAF1 mutants Amyloid fiber formation	Pathway 2 Platelet degranulation Dissolution of Fibrin Clot	Drugs 1 Alteplase Reteplase Anistreplase Tenecteplase Sucralfate Zinc Alfimeprase Ancrod EP-2104R Lanoteplase Thrombin Prothrombin Human thrombin Thrombin alfa Anti-inhibitor coagulant complex Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2 Ocriplasmin Copper	Diseases 1 Familial amyloidosis Inherited thrombophilia Afibrinogenemia; Dysfibrinogenemia	Diseases 2 Alpha-2-plasmin inhibitor (a2-PI) deficiency
Novel Novel	Symbols FLNA and CMIP	Name 1 filamin A	Name2 c-Maf inducing protein	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2	Drugs 1 Artenimol	Drugs 2	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel Novel	Symbols FLNA and ITGB6	Name 1 filamin A	Name2 integrin subunit beta 6	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Elastic fibre formation Molecules associated with elastic fibres Integrin cell surface interactions TGF-beta receptor signaling activates SMADs ECM proteoglycans	Drugs 1 Artenimol	Drugs 2 PLN-74809	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel Novel	Symbols FLNA and ITGB7	Name 1 filamin A	Name2 integrin subunit beta 7	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions	Drugs 1 Artenimol	Drugs 2 R1295 Vedolizumab Etrolizumab	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel Novel	Symbols FLNA and MTNR1A	Name 1 filamin A	Name2 melatonin receptor 1A	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Class A/1 (Rhodopsin-like receptors) G alpha (i) signalling events	Drugs 1 Artenimol	Drugs 2 Ramelteon Melatonin Resveratrol Agomelatine Tasimelteon	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel Novel	Symbols FLNA and GRM8	Name 1 filamin A	Name2 glutamate metabotropic receptor 8	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 G alpha (i) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors)	Drugs 1 Artenimol	Drugs 2 Glutamic acid	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel Novel	Symbols FLNA and GRM5	Name 1 filamin A	Name2 glutamate metabotropic receptor 5	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 G alpha (q) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors) Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 Artenimol	Drugs 2 Acamprosate ADX10059 Rufinamide Dipraglurant	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel Novel	Symbols FLNA and TLR10	Name 1 filamin A	Name2 toll like receptor 10	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Toll Like Receptor 10 (TLR10) Cascade IRAK4 deficiency (TLR5) MyD88 cascade initiated on plasma membrane	Drugs 1 Artenimol	Drugs 2	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel Novel	Symbols FLNA and OPRM1	Name 1 filamin A	Name2 opioid receptor mu 1	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Opioid Signalling G-protein activation Peptide ligand-binding receptors G alpha (i) signalling events Interleukin-4 and Interleukin-13 signaling MECP2 regulates neuronal receptors and channels	Drugs 1 Artenimol	Drugs 2 Tramadol Morphine Codeine Amitriptyline Hydromorphone Methadone Meperidine Oxycodone Levallorphan Dextromethorphan Butorphanol Dextropropoxyphene Pentazocine Naltrexone Sufentanil Alfentanil Fentanyl Loperamide Nalbuphine Levorphanol Remifentanil Ondansetron Anileridine Buprenorphine Hydrocodone Diphenoxylate Naloxone Oxymorphone Dezocine Ketamine Levacetylmethadol Aripiprazole Methadyl acetate 3-Methylthiofentanyl Dimethylthiambutene Diamorphine Ethylmorphine Etorphine Carfentanil Diprenorphine Dihydromorphine 3-Methylfentanyl V1003 Epicept NP-1 LI-301 Tapentadol Nalmefene Alvimopan Amisulpride Morphine glucuronide Ketobemidone Methylnaltrexone Naloxegol Cannabidiol Trimebutine Butyrfentanyl Pholcodine Eluxadoline Tianeptine Opium Pentoxyverine Naldemedine Samidorphan Metenkefalin Medical Cannabis Nabiximols Loxicodegol Oliceridine	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel Novel	Symbols FLNA and GRIK1	Name 1 filamin A	Name2 glutamate ionotropic receptor kainate type subunit 1	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Activation of Na-permeable kainate receptors Activation of Ca-permeable Kainate Receptor	Drugs 1 Artenimol	Drugs 2 Glutamic acid Butabarbital Topiramate Tezampanel	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel Novel	Symbols FGFR1 and GRB14	Name 1 fibroblast growth factor receptor 1	Name2 growth factor receptor bound protein 14	Pathway 1 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Pathway 2 Tie2 Signaling	Drugs 1 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Drugs 2	Diseases 1 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate	Diseases 2
Novel Novel	Symbols FGFR1 and PDK1	Name 1 fibroblast growth factor receptor 1	Name2 pyruvate dehydrogenase kinase 1	Pathway 1 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Pathway 2 Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid Mitochondrial protein degradation	Drugs 1 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Drugs 2 4-[(3-CHLORO-4-{[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]AMINO}PHENYL)SULFONYL]-N,N-DIMETHYLBENZAMIDE Dichloroacetic acid	Diseases 1 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate	Diseases 2
Novel Novel	Symbols FGFR1 and NRP1	Name 1 fibroblast growth factor receptor 1	Name2 neuropilin 1	Pathway 1 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Pathway 2 Neurophilin interactions with VEGF and VEGFR Signaling by ROBO receptors Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling Signal transduction by L1 CHL1 interactions Attachment and Entry	Drugs 1 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Drugs 2	Diseases 1 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate	Diseases 2
Novel Novel	Symbols SFN and MARK3	Name 1 stratifin	Name2 microtubule affinity regulating kinase 3	Pathway 1 Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane RHO GTPases activate PKNs TP53 Regulates Metabolic Genes TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex Regulation of localization of FOXO transcription factors SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways	Pathway 2 RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Transcriptional and post-translational regulation of MITF-M expression and activity	Drugs 1	Drugs 2 Fostamatinib	Diseases 1	Diseases 2
Novel Novel	Symbols NR3C1 and MAFF	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 MAF bZIP transcription factor F	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2 Factors involved in megakaryocyte development and platelet production Factors involved in megakaryocyte development and platelet production	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel Novel	Symbols NR3C1 and ABCC1	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 ATP binding cassette subfamily C member 1 (ABCC1 blood group)	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2 Sphingolipid de novo biosynthesis Heme degradation Synthesis of Leukotrienes (LT) and Eoxins (EX) ABC-family proteins mediated transport Cytoprotection by HMOX1 Paracetamol ADME Transport of RCbl within the body NFE2L2 regulating MDR associated enzymes	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2 ATP Sulfinpyrazone Biricodar Romidepsin Leukotriene C4	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel Novel	Symbols NR3C1 and SPIN2A	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 spindlin family member 2A	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel Novel	Symbols NR3C1 and UHRF1	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 ubiquitin like with PHD and ring finger domains 1	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2 DNA methylation Chromatin modifications during the maternal to zygotic transition (MZT)	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel	Symbols FTL and GLP1R	Name 1 ferritin light chain	Name2 glucagon like peptide 1 receptor	Pathway 1 Scavenging by Class A Receptors Golgi Associated Vesicle Biogenesis Neutrophil degranulation Iron uptake and transport	Pathway 2 Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Glucagon-like Peptide-1 (GLP1) regulates insulin secretion G alpha (s) signalling events Glucagon-type ligand receptors	Drugs 1 Iron Dextran Protoporphyrin Ferric pyrophosphate Sodium ferric gluconate complex Ferric pyrophosphate citrate	Drugs 2 Glucagon Exenatide Liraglutide Albiglutide Dulaglutide Lixisenatide Semaglutide Taspoglutide Tirzepatide Efpeglenatide Glutazumab	Diseases 1 Neurodegeneration with brain iron accumulation (NBIA); Hallervorden-Spatz syndrome; Neuroferritinopathy; Aceruloplasminemia	Diseases 2
Novel	Symbols FGA and SYCE1L	Name 1 fibrinogen alpha chain	Name2 synaptonemal complex central element protein 1 like	Pathway 1 Platelet degranulation ER-Phagosome pathway Common Pathway of Fibrin Clot Formation MyD88:MAL(TIRAP) cascade initiated on plasma membrane Integrin cell surface interactions Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) MAP2K and MAPK activation Regulation of TLR by endogenous ligand Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Post-translational protein phosphorylation Signaling downstream of RAS mutants Signaling by RAF1 mutants Amyloid fiber formation	Pathway 2	Drugs 1 Alteplase Reteplase Anistreplase Tenecteplase Sucralfate Zinc Alfimeprase Ancrod EP-2104R Lanoteplase Thrombin Prothrombin Human thrombin Thrombin alfa Anti-inhibitor coagulant complex Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Familial amyloidosis Inherited thrombophilia Afibrinogenemia; Dysfibrinogenemia	Diseases 2
Novel	Symbols FGA and SERPINF2	Name 1 fibrinogen alpha chain	Name2 serpin family F member 2	Pathway 1 Platelet degranulation ER-Phagosome pathway Common Pathway of Fibrin Clot Formation MyD88:MAL(TIRAP) cascade initiated on plasma membrane Integrin cell surface interactions Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) MAP2K and MAPK activation Regulation of TLR by endogenous ligand Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Post-translational protein phosphorylation Signaling downstream of RAS mutants Signaling by RAF1 mutants Amyloid fiber formation	Pathway 2 Platelet degranulation Dissolution of Fibrin Clot	Drugs 1 Alteplase Reteplase Anistreplase Tenecteplase Sucralfate Zinc Alfimeprase Ancrod EP-2104R Lanoteplase Thrombin Prothrombin Human thrombin Thrombin alfa Anti-inhibitor coagulant complex Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2 Ocriplasmin Copper	Diseases 1 Familial amyloidosis Inherited thrombophilia Afibrinogenemia; Dysfibrinogenemia	Diseases 2 Alpha-2-plasmin inhibitor (a2-PI) deficiency
Novel	Symbols FLNA and CMIP	Name 1 filamin A	Name2 c-Maf inducing protein	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2	Drugs 1 Artenimol	Drugs 2	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel	Symbols FLNA and ITGB6	Name 1 filamin A	Name2 integrin subunit beta 6	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Elastic fibre formation Molecules associated with elastic fibres Integrin cell surface interactions TGF-beta receptor signaling activates SMADs ECM proteoglycans	Drugs 1 Artenimol	Drugs 2 PLN-74809	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel	Symbols FLNA and ITGB7	Name 1 filamin A	Name2 integrin subunit beta 7	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions	Drugs 1 Artenimol	Drugs 2 R1295 Vedolizumab Etrolizumab	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel	Symbols FLNA and MTNR1A	Name 1 filamin A	Name2 melatonin receptor 1A	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Class A/1 (Rhodopsin-like receptors) G alpha (i) signalling events	Drugs 1 Artenimol	Drugs 2 Ramelteon Melatonin Resveratrol Agomelatine Tasimelteon	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel	Symbols FLNA and GRM8	Name 1 filamin A	Name2 glutamate metabotropic receptor 8	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 G alpha (i) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors)	Drugs 1 Artenimol	Drugs 2 Glutamic acid	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel	Symbols FLNA and GRM5	Name 1 filamin A	Name2 glutamate metabotropic receptor 5	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 G alpha (q) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors) Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 Artenimol	Drugs 2 Acamprosate ADX10059 Rufinamide Dipraglurant	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel	Symbols FLNA and TLR10	Name 1 filamin A	Name2 toll like receptor 10	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Toll Like Receptor 10 (TLR10) Cascade IRAK4 deficiency (TLR5) MyD88 cascade initiated on plasma membrane	Drugs 1 Artenimol	Drugs 2	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel	Symbols FLNA and OPRM1	Name 1 filamin A	Name2 opioid receptor mu 1	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Opioid Signalling G-protein activation Peptide ligand-binding receptors G alpha (i) signalling events Interleukin-4 and Interleukin-13 signaling MECP2 regulates neuronal receptors and channels	Drugs 1 Artenimol	Drugs 2 Tramadol Morphine Codeine Amitriptyline Hydromorphone Methadone Meperidine Oxycodone Levallorphan Dextromethorphan Butorphanol Dextropropoxyphene Pentazocine Naltrexone Sufentanil Alfentanil Fentanyl Loperamide Nalbuphine Levorphanol Remifentanil Ondansetron Anileridine Buprenorphine Hydrocodone Diphenoxylate Naloxone Oxymorphone Dezocine Ketamine Levacetylmethadol Aripiprazole Methadyl acetate 3-Methylthiofentanyl Dimethylthiambutene Diamorphine Ethylmorphine Etorphine Carfentanil Diprenorphine Dihydromorphine 3-Methylfentanyl V1003 Epicept NP-1 LI-301 Tapentadol Nalmefene Alvimopan Amisulpride Morphine glucuronide Ketobemidone Methylnaltrexone Naloxegol Cannabidiol Trimebutine Butyrfentanyl Pholcodine Eluxadoline Tianeptine Opium Pentoxyverine Naldemedine Samidorphan Metenkefalin Medical Cannabis Nabiximols Loxicodegol Oliceridine	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel	Symbols FLNA and GRIK1	Name 1 filamin A	Name2 glutamate ionotropic receptor kainate type subunit 1	Pathway 1 Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Pathway 2 Activation of Na-permeable kainate receptors Activation of Ca-permeable Kainate Receptor	Drugs 1 Artenimol	Drugs 2 Glutamic acid Butabarbital Topiramate Tezampanel	Diseases 1 FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia	Diseases 2
Novel	Symbols FGFR1 and GRB14	Name 1 fibroblast growth factor receptor 1	Name2 growth factor receptor bound protein 14	Pathway 1 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Pathway 2 Tie2 Signaling	Drugs 1 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Drugs 2	Diseases 1 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate	Diseases 2
Novel	Symbols FGFR1 and PDK1	Name 1 fibroblast growth factor receptor 1	Name2 pyruvate dehydrogenase kinase 1	Pathway 1 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Pathway 2 Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid Mitochondrial protein degradation	Drugs 1 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Drugs 2 4-[(3-CHLORO-4-{[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]AMINO}PHENYL)SULFONYL]-N,N-DIMETHYLBENZAMIDE Dichloroacetic acid	Diseases 1 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate	Diseases 2
Novel	Symbols FGFR1 and NRP1	Name 1 fibroblast growth factor receptor 1	Name2 neuropilin 1	Pathway 1 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Pathway 2 Neurophilin interactions with VEGF and VEGFR Signaling by ROBO receptors Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling Signal transduction by L1 CHL1 interactions Attachment and Entry	Drugs 1 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Drugs 2	Diseases 1 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate	Diseases 2
Novel	Symbols SFN and MARK3	Name 1 stratifin	Name2 microtubule affinity regulating kinase 3	Pathway 1 Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane RHO GTPases activate PKNs TP53 Regulates Metabolic Genes TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex Regulation of localization of FOXO transcription factors SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways	Pathway 2 RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Transcriptional and post-translational regulation of MITF-M expression and activity	Drugs 1	Drugs 2 Fostamatinib	Diseases 1	Diseases 2
Novel	Symbols NR3C1 and MAFF	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 MAF bZIP transcription factor F	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2 Factors involved in megakaryocyte development and platelet production Factors involved in megakaryocyte development and platelet production	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel	Symbols NR3C1 and ABCC1	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 ATP binding cassette subfamily C member 1 (ABCC1 blood group)	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2 Sphingolipid de novo biosynthesis Heme degradation Synthesis of Leukotrienes (LT) and Eoxins (EX) ABC-family proteins mediated transport Cytoprotection by HMOX1 Paracetamol ADME Transport of RCbl within the body NFE2L2 regulating MDR associated enzymes	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2 ATP Sulfinpyrazone Biricodar Romidepsin Leukotriene C4	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel	Symbols NR3C1 and SPIN2A	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 spindlin family member 2A	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2
Novel	Symbols NR3C1 and UHRF1	Name 1 nuclear receptor subfamily 3 group C member 1	Name2 ubiquitin like with PHD and ring finger domains 1	Pathway 1 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription	Pathway 2 DNA methylation Chromatin modifications during the maternal to zygotic transition (MZT)	Drugs 1 Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	Drugs 2	Diseases 1 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency	Diseases 2

Page 23 out of 58 pages

Search Results : Diabetes